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ABSTRACT
Objective: Pelvic lymph node dissection (PLND) is performed alongside radical prostatectomy as the most 
accurate method of staging prostate cancer. Yet the potential therapeutic benefits of lymphadenectomy are 
yet to be confirmed.
Material and methods: A PubMed database search was performed to identify all papers comparing tech-
niques for PLND or none. The primary outcome measure was long term oncological outcomes. Studies 
looking at men with clinically localized prostate cancer at the time of radical prostatectomy who received no 
adjuvant treatment were included. Previous reviews and single case reports were excluded. The subsequent 
available papers were then systematically reviewed.
Results: Limited PLND provides no benefit in low risk prostate cancer and is unlikely to provide a therapeu-
tic benefit in higher risk groups either when compared with no PLND. Extended PLND may provide some 
therapeutic benefit, particularly in patients with occult metastases; however, the evidence base for this is not 
particularly strong and may be down to statistical phenomena.
Conclusion: When performed in prostate cancer patients, PLND should be extended, as it is a more ac-
curate staging tool and may provide therapeutic benefit to some patients. However, to properly assess this, 
randomised controlled studies need to be performed in this area.
Keywords: Pelvic lymph node dissection; prostatectomy; prostate cancer; systematic review; outcomes.
Systematic Review
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Introduction
In the management of prostate cancer (PCa), 
the role of pelvic lymph node dissection 
(PLND) at the time of radical prostatectomy 
has long been debated. Whilst it is reasonably 
well established as the best method for accu-
rate staging of PCa[1], its role in treatment and 
whether it has any therapeutic benefit is still 
widely contested.[2] It has been proposed that 
lymphadenectomy may remove undetectable 
micrometastases and therefore potentially im-
prove survival.[3] Yet the extent of PLND var-
ies greatly between surgeons and centres, with 
some performing a limited PLND (lPLND), 
confined to the external iliac and obturator 
fossa areas, and others choosing an extended 
PLND (ePLND). Even then debate consider 
variability exists in the definition of ePLND 
with some surgeons removing the external il-
iac, hypogastric and obturator nodes and other 
including the pre sacral and pre sciatic nodes.[4] 
Risk of lymph node metastasis in PCa largely 
depends on the patient’s risk group patients at 
the time of diagnosis.[5] In lower risk patients  it 
is often felt that the risks of performing PLND 
outweigh any potential cases. Furthermore in 
comparison to other malignancy such as breast, 
a greater variation in the routes of lymphatic 
spread of cancer is found.[6] The goal of this re-
view is to assess any available papers that look 
at comparing the effects of PLND on the out-
comes of PCa treatment.
Material and methods
A series of PubMed searches were carried out 
between November and December 2015 using 
combinations of the following terms; pelvic lymph node dis-
section, lymphadenectomy, prostatectomy, prostate cancer, out-
come, survival, and treatment. Filters were applied to exclude 
any studies not done in humans. The reference lists from any 
selected papers were also searched for relevant papers that may 
have been missed by the initial searches. 
Papers for inclusion would look at men with clinically local-
ized primary PCa at the time of radical prostatectomy. The 
papers would need to show a direct comparison between 
ePLND and lPLND, or between either of these and no dis-
section at all. lPLND was defined as removal of the exernal 
iliac and obturator nodes, and ePLND as the removal of these 
plus either the hyposgastic, pre-sciatic or pre-sacral nodes or 
any combination thereof. Patients would need to have not re-
ceived any adjuvant therapy during the period of the study. 
Randomised controlled trials and prospective or retrospec-
tive analyses looking at men with PCa from all risk groups 
as stratified by D’Amico[5] would be included. All previous 
reviews were automatically excluded, as were single case 
reports, editorial pieces and titles that were not available in 
English or simply not available.
The outcome measures of interest were: biochemical recurrence 
(BCR), defined as a prostate specific antigen reading of 0.2 or 
greater following radical prostatectomy, cancer specific survival 
(CSS). These were chosen as CSS would be the most definite way 
of assessing the outcome of therapy, but given the long follow up 
time required BCR could be used as an indicator of disease pro-
gression. The search technique is summarised in Figure 1.
Results
In total, sixteen studies were identified that compared PLND 
in terms of outcome. Twelve articles made a direct compari-
son between defined extents of PLND. Of these, seven[7-13] 
compared lPLND with no dissection at all and the remaining 
five[14-18] compared ePLND and lPLND, with one study[18] also 
including no PLND. In some of the studies, the term standard 
PLND was used but in these cases the extent matched that 
of lPLND and so will be referred to as lPLND here. Of the 
twelve, five were exclusively looking at patients in the low 
risk group, two looked at those at intermediate and high risk, 
one in exclusively high risk patients and one across all risk 
groups.
The remaining four[19-22] studies from the total of sixteen used the 
number of lymph nodes removed as a surrogate for the extent of 
dis section and were deemed to have a suitable format for inclu-
sion in the review. 
It is worth noting that there was one paper[23] that was included 
after the literature search but it had actually been retracted due 
to misconduct by one of the authors and was no longer available.
A significant degree of clinical and methodological hetero-
geneity was seen across all studies which prevented pooled 
analysis of the results. Throughout the studies, there was a 
great degree of variance in the methodology used, including 
patient groups, length of follow up and outcome measures, 
which made direct comparison between the papers (with the 
exception of the updates) very challenging. Comparable data 
taken from the direct comparison studies are presented in 
Table 1.
lPLND vs. no PLND
Of the 7 studies studies that compared lPLND with no PLND in 
exclusively low risk patients, PLND showed no benefit in terms 
of BCR. Fergany et al.[7], Bhatta-Dhar et al.[8] and Weight et al.[9] 
were a series of papers following the same group of patients 
over 4, 6 and 10 years respectively. At no stage did they find 
any significant difference in BCR free survival rates (BCRFS) 
between lPLND and none, finding 4, 6 and 10-year BCRFS rates 
of 91% vs. 97% (p=0.16), 86% vs. 88% (p=0.28), and 84% and 
88% (p=0.33) respectively. Daimon et al.[12] looked at the same 
risk group but in 139 men who had received laparoscopic pro-
cedures and also saw no statistically significant difference, this 
time at 7 years (88.3% vs. 82.4%, p=0.278). Mitsuzuka et al.[13] 
looked at 222 Japanese men with low risk PCa and found the 5 
year BCRFS rates to be nearly identical between the two groups 
(p=0.65).  
When comparing lPLND with none in 4693 patients across all 
risk groups, Berglund et al.[10] also found no significant differ-
ence in BCRFS at 5 years (74% vs. 70%, p=0.11).  Ku et al.[11] 
Figure 1. PRISMA flow diagram
Pubmed search 
n=833
Title screening 
n=763
Not relevant 
n=673
Abstract screening 
n=90
Not relevant n=44 
Previous review n=14
Full article screening 
n=32
Not relevant n=12 
Not available n=1 
Not in English n=3 
Retracted n=1Included in review 
n=16
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looked at lPLND compared with no PLND in 199 Korean men 
with high risk PCa and found no significant difference in BCRFS 
rates (p=0.355).
lPLND vs. ePLND
When comparing ePLND with lPLND, Allaf et al.[15] looked at 5 
year BCRFS in 4000 patients across all risk groups.  They failed 
Table 1. Summary data of all comparative studies
Paper Year Comparison
Total 
Pts
ePLND/ 
equivalent
lPLND/ 
equivalent 
No 
PLND
Risk 
Groups FU
BCRFS 
ePLND
BCRFS 
lPLND
BCRFS 
No 
PLND p
Bivalacqua  
et al.[17] 2013 ePLND vs. lPLND 4265 2279 1986 - All 126
30.1% @5 
yrs
7.1% 
@5 yrs 0.018*
Kim  
et al.[16] 2013 ePLND vs. lPLND 464 170 294 -
Int. & 
High 36
77.8% @3 
yrs
73.5% 
@3 yrs 0.497
Liss  
et al.[18] 2013
ePLND vs. lPLND 
vs. no PLND 492 54 231 207 All 11.6
29.6 % 
@0.8 yrs
14.7% 
@ 1.1 
yrs
3.4 % 
@0.9 
yrs <0.001*
Mitsuzuka  
et al.[13] 2013
lPLND vs. no 
PLND 222 - 147 75 Low 26-60 -
87.6% 
@5 yrs
87.1% 
@5 yrs 0.65
Daimon  
et al.[12] 2012
lPLND vs. no 
PLND 139 - 85 54 Low 69.4 -
88.3% 
@7 yrs
82.4% 
@7 yrs 0.278
Jung et al.[14] 2012 ePLND vs. lPLND 200 45 155 - High 24 - - - -
Ku  
et al.[11] 2011
lPLND vs. no 
PLND 199 - 111 88 High 37.0 - - - 0.355
Schiavina  
et al.[22] 2011
>9 nodes vs. 0-9 
nodes 470 211 259
Int & 
High
58.5% 
@10 yrs 46.4% @10 yrs 0.023*
Schiavina  
et al.[21] 2010
>9 nodes vs. 1-9 
nodes 614 319 295 - All 62.5
Not 
reported
Not 
reported - 0.019*
Berglund  
et al.[10] 2007
lPLND vs. no 
PLND 4693 - 3961 732 All - -
74% @5 
yrs
70% 
@5 yrs 0.11
Weight  
et al.[9] 2007
lPLND vs. no 
PLND 336 - 140 196 Low - -
84% 
@10 yrs
88% 
@10 yrs 0.33
Joslyn and 
Konety[19] 2006
Lymph nodes 
removed vs. none 9182 - - - All +120 - - - *
DiMarco  
et al.[20] 2005
<5 nodes vs.  
5-9 vs. 10-14 vs. 
15-19 vs. >19 7036 - - - All 69.6 - - - -
Bhatta-Dhar  
et al.[8] 2004
lPLND vs. no 
PLND 336 - 140 196 Low 60
86% @6 
yrs
88% 
@6 yrs 0.28
Allaf  
et al.[15] 2004 ePLND vs. lPLND 4000 2135 1865 - All -
34.4% @5 
yrs
16.5% 
@5 yrs 0.07
Fergany  
et al.[7] 2000
lPLND vs. no 
PLND 575 - 372 203 Low 38
91% @4 
yrs
97% 
@4 yrs 0.16
Key: Pts: patients, FU: Average (median/mean) Follow up, BCRFS: Biochemical recurrence free survival Int: Intermediate Risk Group
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to find any significant difference between the two techniques 
though they reported a trend towards increased survival in those 
who received ePLND (34.4% vs. 16.5, p=0.07). Further analysis 
showed that there was a significant difference in BCRFS at 5 
years (42.9% vs. 10.0%, p=0.01) in a subgroup of men found 
to have positive lymph nodes in less than 15% of the nodes re-
moved.  In a later paper, Bivalacqua et al.[17] reported these re-
sults with a follow up of 10.5 years. They showed a significant 
finding for 5-year BCRFS rates at 30.1% vs. 7.1% (p=0.018) and 
a trend towards improved CSS at 10 years for the ePLND group 
(83.6% vs. 52.6%, p=0.199). In subsequent analysis with Cox 
proportional hazard models, the proposed benefit to BCRFS 
lost its significance though they still reported a trend, (hazard 
ratio (HR): 0.596; 95% confidence interval (CI) 0.313-1.034; 
p=0.064) and there was no difference seen for CSS (HR: 0.495; 
CI 0.163-1.504;p=0.215). Again, in the subset of patients with 
node positive disease and less than 15% involvement in sampled 
nodes, they reported significant differences in BCRFS at 5 years, 
with the ePLND subgroup rate at 39.4% and the lPLND rate 
at 0.0% (p=0.003). This gave a HR of 0.350 (CI: 0.150-0.819; 
p=0.016). 
Liss et al.[18] looked at ePLND compared with lPLND during 
robot assisted radical prostatectomy and also compared this 
to those who received no PLND. With 492 patients across 
all risk groups they found that ePLND was significantly as-
sociated with an increased risk of BCR (p=0.001, depicted 
in a Kaplan-Meier graph).  However after multivariate anal-
ysis adjusting for the fact that high-risk patients were more 
likely to receive an ePLND this association disappeared 
(p=0.294). 
Kim et al.[16] looked at ePLND versus lPLND in 464 inter-
mediate and high-risk patients that received robot assisted 
surgery. They propensity score matched the groups to try and 
eliminate some of the bias associated with retrospective anal-
ysis. They found that in the whole cohort the 3 year BCRFS 
in the ePLND group was lower than the lPLND group (72.7% 
vs. 79.8%, HR: 1.48, CI 1.00-2.18, p=0.048), however, in the 
matched cohort they reported that this reversed and suggest-
ed a trend towards favouring ePLND (77.8% vs. 73.5%, HR: 
0.85, CI0.52-1.36, p=0.497) although this wasn’t statistically 
significant. 
When exclusively looking at 200 patients from the high-risk 
group, Jung et al.[14] showed greater rates of diagnosis of lymph 
node metastasis with ePLND but failed to show improved 
BCRFS compared to lPLND. The study was limited by the me-
dian follow up was just 24 months (interquartile range (IQR): 
15-34) and 13 months (IQR: 10-17) respectively. 
In the papers that used the number of nodes removed as a surro-
gate for the extent of dissection, Joslyn and Konety[19] identified 
9,182 patients in the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results Program who had undergone 
radical prostatectomy with a recorded number of lymph nodes 
removed and a minimum 10 years follow up. They found that 
CSS was improved in all patients that received PLND and had 
more than 4 nodes removed compared to 3 or less (HR: 0.77, 
CI 0.64-0.93, p=0.0069), and that CSS in patients found to have 
negative nodes after PLND improved if 10 or greater nodes were 
removed (HR: 0.85 CI, 0.72-0.99, p=0.03282). 
Similarly, Schiavina et al.[21] found that in node negative pa-
tients, those with 10 or greater nodes removed had improved 
BCRFS than those with less taken (HR 0.564, CI 0.390-0.814, 
p=0.002).  Another paper from the same author and institution[22] 
looking at intermediate and high-risk groups found that 10 or 
greater nodes removed was associated with a benefit to BCRFS 
rates at 10 years here too (58.5% vs. 46.4%, p=0.023). They also 
reported significance when looking at 33 patients found to have 
less than 2 positive nodes, with 10-year BCRFS rates of 43.3% 
for those with greater than 10 nodes removed compared to 0.0% 
for those with 1-9 nodes removed (p=0.014). Conversely, Di-
Marco et al.[20] found that when looking at 7036 patients with 
negative lymph nodes over a median follow up of 69 months, 
there was no association between increased lymph node dissec-
tion and improved BCRFS across all risk groups (Risk ratio: 
0.99, CI 0.98-1.02, p=0.062).
Discussion
With PCa being the highest incidence cancer in men it is vital 
that treatment is effective. It is important to assess if PLND is 
part of the therapy, and not just in the staging the disease. Bader 
et al.[3] found PCa patients treated with surgery alone had disease 
free rates at ten years that compared favourably with those who 
received adjuvant treatment. They theorised that PLND may re-
move occult metastases from patients and prevent progression or 
recurrence. The aim of this review has been to assess the avail-
able data that directly compares the extents of PLND performed.
From the papers reviewed here, Fergany et al.[7], Bhatta-Dhar 
et al.[8], Weight et al.[9], Daimon et al.[12] and Mitsuzuka et al.[13] 
all conclude that there is no need to perform lPLND in low risk 
PCa patients. There are a number of issues with all these papers 
beyond the selection bias that comes with their retrospective ap-
proach. All were performed in single centres and have fairly low 
number of patients included. Despite this, their results were con-
sistent and there are no studies that disagree with their findings. 
Similarly, Berglund et al.[10] and Ku et al.[11] found no benefit to 
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lPLND across other risk groups so it would seem sound to con-
clude that there is no need to perform lPLND in any patient with 
PCa. This is supported further by other studies that show the 
use of just lPLND removes significantly less lymph nodes than 
ePLND and is not as accurate a staging tool.[24] Concerns that 
ePLND may cause more complications appear to be unfounded 
as recent studies show a similar incidence of complications be-
tween the two extents.[24,25] Whether ePLND can be of benefit 
to low risk PCa patients cannot be assessed as no studies have 
looked into this area, however, current European guidance states 
that if PLND is to be performed at all it should be extended[26] 
but there is no need to perform PLND in men from the low risk 
group as they are at very low risk of metastasis[27] and potential 
complications outweigh any benefits.
In the case of ePLND, evidence is inconclusive. Jung et al.[14] 
stated that there was no extra benefit in performing an extended 
dissection, however, the follow up time used was too short and 
while a supporting paper by DiMarco et al.[20] had an appropri-
ate length of follow up time at 5.8 years and a suitable study 
size, its use of number of nodes as a surrogate for the extent 
of PLND and variability in the PLNDs performed by the 5 sur-
geons make firm conclusions difficult to draw. Its findings are 
also at odds with the other papers using similar methods. Jos-
lyn and Konety[19] and the two papers from Schiavina et al.[21,22] 
also used the surrogate measure for dissection extent but did 
find an improvement in outcomes. They also both found partic-
ular improvement in patients who had minimal positive nodal 
involvement, which was echoed in Allaf et al.[15] and the fol-
low up to this paper.[17] It is possible that in these patients with 
minimal disease, the removal of more nodes from more sites 
can remove micrometastases undetectable at biopsy and there-
fore completely remove the disease. This still however needs 
to be approached cautiously due to a statistical phenomenon 
called the Will Rogers effect, in which the moving of data from 
one group to another has the effect of raising the average in 
both. In relation to these studies, patients who received only 
lPLND may have been incorrectly classified as having node 
negative disease that would have been diagnosed with a more 
extensive dissection. As the patients in these studies did not 
receive any adjuvant hormonal or radiotherapy, the perception 
could be one of an improved outcome due to the ePLND when 
it is actually down to stage migration.
The studies as a whole have many issues.  The most striking 
being that they are all retrospective analyses. This makes all 
of them open to various biases, particularly selection bias and 
information bias that could confound results. Another issue is 
that no power calculations are given in any of the papers, with 
only two[19,20] mentioning that they believed their study to be 
suitably powered. The number of patients included in the ma-
jority was below 500 patients, and of the five that had in excess 
of 4000 patients, 3 looked at data across a range of surgeons 
without clarifying what the exact techniques of the surgeons 
were. The largest study[19] used a database that lacked informa-
tion on whether patients had also been treated with adjuvant 
hormonal therapy, which the other studies had all used as an 
exclusion criterion when selecting patients, which could again 
confound results.
Furthermore, the outcome measure for the vast majority of 
studies was BCR, with only Bivalacqua et al.[17] and Joslyn and 
Konety[19] looking at CSS. Whilst BCR is a helpful endpoint and 
can be used clinically to find PCa recurrence well before meta-
static disease, many men who have BCR may not experience 
any symptoms associated with a recurrence of PCa and likewise 
many will not die from it.[28] How clinically relevant BCR there-
fore is in terms of measuring the therapeutic benefit of PLND is 
questionable. The far more meaningful endpoint would be CSS, 
but as the course of PCa can be in excess of 15 years[29] this was 
well beyond the design of the studies featured here and any fu-
ture study would require a lot of long term planning.
It is worth noting that a review in 2005 on the role PLND in 
PCa[30] acknowledged the potential therapeutic benefit but stated 
that randomised controlled studies would be required to prop-
erly assess this, and yet a decade later none have been done. To 
date, the only randomised study in the area was performed by 
Clark et al.[31] in 2003 where they performed both ePLND and 
lPLND in the same patients, but did not look at BCR rates. With 
this lack of robust studies, it is interesting to note that two tri-
als are listed on ClinicalTrials.gov that will randomise patients 
to either ePLND or lPLND and the results from these will be 
awaited with interest.
In conclusion, from this limited data set, it is possible to con-
clude that lPLND is of no therapeutic benefit during radical 
prostatectomy for prostate cancer. An ePLND may have a 
therapeutic benefit in terms of BCR, particularly in a subset 
of patients with minimal nodal disease, and in keeping with 
current guidelines when PLND is performed in intermediate 
and high risk patients it should be extended. However, the 
evidence for any potential benefit is not strong and may be 
down to stage migration from more accurate staging of the 
cancer and whether any benefit in BCR reduction translates 
into increased cancer specific survival remains to be seen. Ran-
domised controlled studies are needed to establish answers to 
these questions but as these are awaited, ePLND can continue 
to be used in intermediate and high-risk patients as the most 
accurate staging method for prostate cancer.
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